OakChart

Karyopharm Therapeutics Inc

KPTIHealthcare·Biotechnology·USA·Nano·NASD·Nov 10 • 4:00 PM ET

0.01740.0000 (0.00%)
2026-11-11 14:25 CET
Market cap
0.39 USD m
Revenue, TTM
146.62 USD m
Net income, TTM
-224.74 USD m
Free cash flow, TTM
-65.35 USD m
EPS diluted, TTM
-13.08
P/E
-
Compare

Price

KPTI against its 20, 50 and 200-day averages
2050200beatmiss
0.002.505.007.5010.0073.4M146.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KPTIclose 0.0220-day 0.3550-day 0.96200-day 5.810.02

99.8% under 10.99 on 24 Feb 2026. Last 15 sessions, 5705.9% high to low

Profile

KPTI
52-week range, 0% of the way up
0.0210.99

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

IndexRUT
Employees228
IPONov 06, 2013
Beta1.34
ATR, 14d0.13
Rel volume0.00
Short float43.67%
Insider own16.91%
Inst own79.40%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap0.39M
Enterprise Value191.47M
Income-224.74M
Sales146.62M
Book/sh-14.56
Cash/sh2.90
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees228
IPONov 06, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S0.00
P/B-
P/C0.01
P/FCF-
EV/EBITDA-
EV/Sales1.31
Quick Ratio0.76
Current Ratio0.79
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / No

Earnings

EPS (ttm)-13.08
EPS next Y-0.94
EPS next Q-0.34
EPS this Y72.76%
EPS next Y80.76%
EPS next 5Y91.77%
EPS past 3/5Y16.03% 15.19%
Sales past 3/5Y-2.39% 6.21%
EPS Y/Y TTM11.95%
Sales Y/Y TTM6.81%
EPS Q/Q46.41%
Sales Q/Q-11.86%
EarningsAug 13 BMO
EPS/Sales Surpr.-69.13% 3.85%

Ownership

Insider Own16.91%
Insider Trans-0.23%
Inst Own79.40%
Inst Trans9.67%
ROA-207.90%
ROE-
ROIC-
Gross Margin95.89%
Oper. Margin-56.17%
Profit Margin-153.28%
SMA20-95.05%
SMA50-98.19%
SMA200-99.70%
Trades-

Technical

Shs Outstand22.68M
Shs Float18.85M
Short Float43.67%
Short Ratio0.98
Short Interest8.23M
52W High10.99 -99.84%
52W Low0.02 2.35%
Volatility48.88% 36.76%
ATR (14)0.13
RSI (14)28.03
Beta1.34
Rel Volume0.00
Avg Volume8.43M
Volume0

Performance

Perf Week-80.29%
Perf Month-96.56%
Perf Quarter-99.14%
Perf Half Y-99.80%
Perf YTD-99.76%
Perf Year-99.68%
Perf 3Y-99.84%
Perf 5Y-99.99%
Perf 10Y-99.99%
Recom1.00
Target Price15.00
Prev Close0.02
Price0.02
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 31, 2026DowngradeRRobert W. BairdOutperform → Neutral$3+17,141.4%
Jul 31, 2026DowngradeHH.C. WainwrightBuy → Neutral$3+17,141.4%
Mar 10, 2026InitiatedRRodman & RenshawBuy$28+160,819.5%
Feb 05, 2026InitiatedCCantor FitzgeraldOverweight
Oct 13, 2025UpgradeHH.C. WainwrightNeutral → Buy$15+86,106.9%
Jul 16, 2025DowngradeHH.C. WainwrightBuy → Neutral
Jul 11, 2025ResumedHH.C. WainwrightBuy$27+155,072.4%
Jan 19, 2023InitiatedPPiper SandlerOverweight$8+45,877.0%
Nov 04, 2022UpgradeRRBC Capital MktsSector Perform → Outperform$7 → $10+57,371.3%
Feb 09, 2022UpgradeJJP MorganUnderweight → Neutral$8+45,877.0%

Peers

Mkt cap
TickerCompanyMkt cap
PBYIPuma Biotechnology Inc456.29M
GERNGeron Corp631.36M
CHRSCoherus Oncology Inc100.45M
VSTMVerastem Inc1.12B
SNDXSyndax Pharmaceuticals Inc859.77M
RIGLRigel Pharmaceuticals826.82M
KURAKura Oncology Inc722.37M
BYSIBeyondSpring Inc23.84M
SLSSELLAS Life Sciences Group Inc1.73B
CRISCuris Inc4.41M

Insider trading

latest 14 of 18
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Abate KristinChief Accounting OfficerOct 16 '26Sale0.344,7881,64718,616Oct 19 04:03 PM
Abate KristinChief Accounting OfficerOct 01 '26Sale1.1937845023,404Oct 02 04:01 PM
Abate KristinChief Accounting OfficerSep 01 '26Sale2.02193823,782Sep 02 04:57 PM
Poulton StuartEVP, Chief Development OfficerJul 28 '26Sale7.101891,34294,632Jul 30 04:42 PM
Poulton StuartEVP, Chief Development OfficerMay 14 '26Sale9.504033,82894,821May 15 04:08 PM
Rangwala ReshmaEVP & Chief Medical OfficerMay 14 '26Sale9.504083,87656,829May 15 04:07 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerMay 14 '26Sale9.503243,078107,940May 15 04:05 PM
Abate KristinChief Accounting OfficerMay 14 '26Sale9.505350423,801May 15 04:04 PM
Paulson Richard A.President and CEOMay 14 '26Sale9.502,20320,928269,747May 15 04:03 PM
Mano MichaelEVP, CLO&SecretaryMay 14 '26Sale9.502662,52794,398May 15 04:02 PM
Rangwala ReshmaEVP & Chief Medical OfficerApr 21 '26Sale8.944494,01456,290Apr 22 04:03 PM
Mano MichaelEVP, CLO&SecretaryMar 02 '26Sale9.413,52633,17893,964Mar 03 04:28 PM
Rangwala ReshmaEVP & Chief Medical OfficerMar 02 '26Sale9.415,06647,66956,739Mar 03 04:25 PM
Paulson Richard A.President and CEOMar 02 '26Sale9.4112,361116,311267,030Mar 03 04:21 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
VXFVanguard Extended Market Index ETFAUM: 30.61B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.30B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.44B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.92M
VTHRVanguard Russell 3000 Index ETFAUM: 4.81B

News

latest 14 of 206
  • Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH) (PR Newswire) -17.44%
  • Karyopharm, deep in debt, to sell itself in bankruptcy (BioPharma Dive) -83.08%
  • Karyopharm Therapeutics Files for Chapter 11 Bankruptcy and Agrees to Planned Merger with Ayrmid (InvestorsHub)
  • Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future (PR Newswire)
  • Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -28.95% -7.45%
  • Loading…
  • Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use (BioPharma Dive)
  • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -10.19%
  • Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis (PR Newswire) +10.16%
  • Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... (GuruFocus.com)
  • Karyopharm Therapeutics: Q2 Earnings Snapshot (Associated Press)
  • Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission (PR Newswire)
  • Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 (PR Newswire) -7.55%
  • Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-2.320-1.372-2.32033.4332.196
2026Q12026-05-14-1.240-1.417-1.23635.0731.407
2025Q42026-02-12-5.710-1.994-5.70834.0835.107
2025Q32025-11-03-3.820-3.466-3.82144.0442.066
2025Q22025-08-11-4.320-4.082-4.32237.9338.036
2025Q12025-05-12-2.770-4.419-2.77030.0235.127
2024Q42025-02-19-3.600-3.921-3.66830.5435.677
2024Q32024-11-05-3.900-3.944-3.84838.7837.927
2024Q22024-08-06-3.000-4.469-2.97242.7936.217
2024Q12024-05-08-4.800-5.009-4.85433.1334.487
2023Q42024-02-29-5.400-4.650-5.46833.7535.407
2023Q32023-11-02-4.500-4.200-4.52436.0137.2710
2023Q22023-08-02-4.350-5.133-4.28637.5835.679
2023Q12023-05-04-4.500-5.511-4.51138.7036.329
2022Q42023-02-15-6.450-5.295-6.42233.5834.4310
2022Q32022-11-03-6.750-8.484-6.79336.1534.839

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-48.300-46.988-48.32340.8939.04
2020FY-40.800-41.160-40.865108.09101.43
2021FY-24.750-39.245-24.746209.82133.12
2022FY-30.300-28.395-30.284157.07157.96
2023FY-18.750-17.957-18.793146.03147.69
2024FY-13.950-10.307-9.407145.24150.37
2025FY-17.930-12.224-17.930146.07147.1
2026FY--4.885--137.8
2027FY--0.940--164
2028FY--0.010--574.5
2029FY-1.230--1,572
2030FY-1.770--2,397

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-0710032.8032.8032.80
2026Q3S2026-11-0530033.1231.9634.59
2026Q3S2026-11-0240033.4931.9634.60
2026Q3S2026-10-2750033.5431.9634.60
2026Q3S2026-10-2652033.5431.9634.60
2026Q3S2026-10-1352033.5431.9634.60
2026Q3S2026-08-1452133.5431.9634.60
2026Q3S2026-08-1362133.6231.9634.60
2026Q3S2026-07-3060132.9329.9034.60
2026Q3S2026-07-2860034.2329.9039.76
2026Q3S2026-07-2061334.2329.9039.76
2026Q3S2026-07-0671433.8429.9039.76
2026Q3S2026-06-1671433.8429.9039.76
2026Q3S2026-06-1071433.8529.9039.80

Estimate history

EPS, annual-42.15-47.115-48.323-40.865-24.746-30.284-18.793-9.407-17.928-13.0816
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.972-3.848-3.668-2.77-4.322-3.821-5.708-1.236-2.316
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual1.60530.33640.893108.085209.819157.074146.033145.237146.067146.62
Period201720182019202020212022202320242025TTM
Sales, quarterly42.78638.78330.54230.01537.92944.04434.07935.06633.432
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual3.3024.0554.3584.9285.057.5487.6618.41318.31122.68
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.3098.3548.4138.5688.6478.70218.31122.54422.68
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue146.62146.07145.24146.03157.07209.82108.0840.8930.34
Cost of Goods Sold Incl. D&A6.036.256.355.475.834.193.683.38-
Gross Profit140.59139.82138.89140.56151.24205.63104.4137.51-
Selling, General and Administrative Excl. Other222.79230.53258.33270.10293.44296.54276.26226.79209.48
Research and Development120.81125.32142.89138.22148.04152.70149.84121.37161.37
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-82.20-90.71-119.44-129.54-142.20-90.92-171.85-189.28-179.88
Interest Expense49.3245.8537.4223.8225.0026.0527.1415.652.49
Unusual Expense-62.37-44.700.00-0.287.260.00--
Net Income Before Taxes-224.77-196.00-76.36-142.78-164.92-123.82-195.96-199.55-178.38
Income Taxes-0.030.040.060.320.370.270.310.040.03
Consolidated Net Income-224.74-196.04-76.42-143.10-165.29-124.09-196.27-199.59-178.41
Net Income From Continuing Operations-224.74-196.04-76.42-143.10-165.29-124.09-196.27-199.59-178.41
Net Income-224.74-196.04-76.42-143.10-165.29-124.09-196.27-199.59-178.41
EPS (Recurring)-8.05-13.94-13.26-18.79-30.32-23.73-40.87-48.32-47.11
EPS (Basic, Before Extraordinaries)-12.86-17.93-9.41-18.79-30.28-24.75-40.87-48.32-47.11
EPS (Diluted)-13.08-17.93-9.41-18.79-30.28-24.75-40.87-48.32-47.11
EBITDA-82.05-90.41-119.10-129.01-141.58-90.13-170.88-188.30-179.15
Non-Operating Income (Expense)-30.732.9235.8010.592.000.413.035.374.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.2011.1014.5617.1535.4029.7824.4111.1613.65
Price To Sales Ratio1.930.550.570.681.772.3110.3229.0417.54
Gross Margin95.8995.7295.6396.2596.2998.0096.6091.73-
Operating Margin-56.17-62.10-82.24-88.71-90.53-43.33-159.00-462.85-592.97
Net Margin-153.28-134.21-52.62-97.99-105.23-59.14-181.59-488.08-588.10
Shares Outstanding22.6818.318.417.667.555.054.934.364.06
Market Capitalization0.390.3985.3599.06275.49487.051,144.331,253.15569.97

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue33.4335.0734.0844.0437.9330.0230.5438.78
Cost of Goods Sold Incl. D&A1.081.361.502.231.131.381.411.38
Gross Profit32.3533.7132.5841.8136.8028.6429.1337.40
Selling, General and Administrative Excl. Other54.8760.4750.4257.0361.1961.8960.4163.68
Research and Development28.9633.7827.6530.4232.7134.5433.2236.05
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.53-26.76-17.84-15.22-24.39-33.26-31.28-26.28
Interest Expense13.1412.5512.6211.0111.2310.9911.2011.38
Unusual Expense0.00-62.370.000.000.000.000.00
Net Income Before Taxes-67.02-22.39-102.27-33.09-37.21-23.43-30.89-32.04
Income Taxes0.000.00-0.070.030.040.04-0.110.03
Consolidated Net Income-67.02-22.39-102.20-33.13-37.25-23.46-30.78-32.07
Net Income From Continuing Operations-67.02-22.39-102.20-33.13-37.25-23.46-30.78-32.07
Net Income-67.02-22.39-102.20-33.13-37.25-23.46-30.78-32.07
EPS (Recurring)-2.32-1.24-3.27-3.82-4.32-2.77-3.67-3.85
EPS (Basic, Before Extraordinaries)-2.32-1.02-5.71-3.82-4.32-2.77-3.67-3.85
EPS (Diluted)-2.32-1.24-5.71-3.82-4.32-2.77-3.67-3.85
EBITDA-22.53-26.75-17.82-15.10-24.31-33.18-31.20-26.20
Non-Operating Income (Expense)-31.3516.92-9.44-6.87-1.6020.8211.605.62
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.522.383.082.212.992.813.052.42
Price To Sales Ratio1.930.910.900.400.270.220.590.70
Gross Margin96.7596.1395.5994.9397.0295.4195.3896.43
Operating Margin-67.38-76.31-52.36-34.56-64.30-110.80-102.42-67.77
Net Margin-200.48-63.86-299.89-75.21-98.22-78.17-100.78-82.70
Shares Outstanding22.6822.5418.318.708.658.578.418.35
Market Capitalization0.39102.18125.4956.7137.2431.4885.35104.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments63.74108.74192.10279.03234.96251.72263.07328.20146.67
Short Term Receivables26.1830.7726.9647.0922.5012.887.860.000.00
Inventories4.044.743.044.224.112.640.350.000.00
Other Current Assets9.1912.2411.8119.8214.049.297.296.411.75
Total Current Assets103.15156.49233.92350.16275.61276.53278.57334.61148.42
Net Property, Plant & Equipment4.656.284.887.389.5611.5813.663.862.19
Total Investments and Advances0.350.310.300.630.6424.942.732.7229.69
Intangible Assets---0.00-0.000.000.000.00
Deferred Tax Assets9.04--------
Other Assets0.271.331.330.0019.500.000.000.000.00
Total Assets117.45164.42240.44358.17305.31313.05294.96341.19180.29
Short Term Debt Incl. Current Port. of LT Debt21.9824.863.312.872.321.921.650.000.00
Accounts Payable4.005.113.122.771.604.450.984.335.67
Other Current Liabilities66.0862.2963.0560.2669.8053.8443.7242.5743.80
Total Current Liabilities92.0692.2669.4865.9173.7260.2046.3546.9049.47
Long Term Debt211.63169.66173.71176.20178.26129.21123.06102.660.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities9.04--------
Other Liabilities97.6588.51133.46132.72133.0073.0975.788.451.36
Total Liabilities410.38350.44376.64374.83384.98262.50245.19158.0250.83
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-292.93-186.02-136.21-16.66-79.6750.5549.77183.17129.46
Total Shareholders Equity-292.93-186.02-136.21-16.66-79.6750.5549.77183.17129.46
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-292.93-186.02-136.21-16.66-79.6750.5549.77183.17129.46
Total Liabilities & Stockholders Equity117.45164.42240.44358.17305.31313.05294.96341.19180.29
Book Value Per Share-16.00-22.11-17.78-2.21-15.7810.2611.4245.1739.21
Tangible Book Value Per Share-16.00-22.11-17.78-2.21-15.7810.2611.4245.1739.21
Full-Time Employees228279325385442432347332154
Price to Book Ratio-0.00-0.46-0.99-1.96-6.1122.6425.183.113.21
Return on Assets-139.10-37.75-47.81-49.83-40.13-64.56-62.75-68.42-71.52
Return on Equity------391.29-171.36-114.13-88.43
Return on Invested Capital---381.58-103.60-125.86-109.19-115.48-62.42-99.63
Quick Ratio1.081.643.325.253.684.556.007.133.00
Current Ratio1.121.703.375.313.744.596.017.133.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-224.74-196.04-76.42-143.10-165.29-124.09-196.27-199.59-178.41
Depreciation0.150.300.340.530.620.790.970.970.73
Other Funds (Non Cash)134.3792.10-51.1018.4335.1039.3733.7121.1018.72
Funds from Operations-90.22-103.64-127.18-124.14-129.56-83.93-161.59-177.51-158.95
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital24.8728.27-0.3031.41-19.99-23.191.36-13.31-0.17
Cash from Operating Activities-65.35-75.37-127.49-92.72-149.55-107.12-160.23-190.82-159.12
Capital Expenditures0.000.00-0.140.00-0.12-5.71-0.14-0.21-2.36
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments2.9743.3895.617.94-104.14147.55-53.5478.66-105.30
Purchase of Investments-10.040.00-58.82-159.15-226.02-45.23-274.58-178.49-242.81
Sale Or Maturity of Investments13.0143.38154.44167.09121.88192.78221.04257.14137.51
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities2.9743.3895.477.94-104.26141.84-53.6978.45-107.66
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock58.069.511.451.12193.7413.65172.0850.70149.22
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock58.069.511.451.12193.7413.65172.0850.70149.22
Proceedsfrom Stock Options18.330.000.000.00189.769.90161.7846.19145.71
Issuance or Reduction of Debt, Net20.5420.5440.190.000.0060.000.000.00166.88
Change in Long Term Debt20.5420.5440.190.000.0060.000.000.00166.88
Issuance of Long Term Debt20.7920.7980.710.000.0060.000.000.00166.88
Reduction of Long Term Debt-0.25-0.25-40.520.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.0073.610.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities78.6030.0541.651.12193.7473.65172.08124.31316.11
Exchange Rate Effect0.010.02-0.01-0.03-0.49-0.050.270.02-0.08
Net Change in Cash16.22-1.929.62-83.69-60.56108.32-41.5711.9549.25
Free Cash Flow-65.35-75.37-127.63-92.72-149.67-107.33-160.38-191.03-161.48
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments65.1190.8563.7445.8851.7069.94
Short Term Receivables29.8723.3626.1831.8832.9335.24
Inventories3.993.604.043.974.994.77
Other Current Assets7.418.539.198.038.2510.29
Total Current Assets106.38126.33103.1589.7597.87120.24
Net Property, Plant & Equipment4.354.504.654.805.335.80
Total Investments and Advances0.320.320.350.350.350.34
Deferred Tax Assets--9.04---
Other Assets0.270.270.271.331.331.33
Total Assets111.32131.42117.4596.23104.88127.71
Short Term Debt Incl. Current Port. of LT Debt41.3833.2521.9813.6732.1225.39
Accounts Payable7.664.284.005.392.605.87
Other Current Liabilities85.2079.7766.0868.0964.5059.11
Total Current Liabilities134.23117.3092.0687.1699.2290.37
Long Term Debt214.82197.62211.63182.75158.50161.32
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--9.04---
Other Liabilities92.4482.1497.6595.5886.0981.91
Total Liabilities441.49397.06410.38365.49343.81333.60
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-330.17-265.65-292.93-269.26-238.93-205.88
Total Shareholders Equity-330.17-265.65-292.93-269.26-238.93-205.88
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-330.17-265.65-292.93-269.26-238.93-205.88
Total Liabilities & Stockholders Equity111.32131.42117.4596.23104.88127.71
Book Value Per Share-14.56-11.78-16.00-30.94-27.63-24.03
Tangible Book Value Per Share-14.56-11.78-16.00-30.94-27.63-24.03
Full-Time Employees--228---
Price to Book Ratio-0.00-0.35-0.24-0.24-0.18-0.17
Return on Assets-207.90-150.48-139.10-87.24-77.51-37.64
Quick Ratio0.761.051.080.980.941.28
Current Ratio0.791.081.121.030.991.33

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-67.02-22.39-102.20-33.13-37.25-23.46
Depreciation-0.000.010.020.120.080.08
Other Funds (Non Cash)40.82-4.2084.8512.908.43-14.07
Funds from Operations-26.20-26.58-17.33-20.11-28.75-37.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.273.855.5014.2510.05-1.52
Cash from Operating Activities-24.93-22.73-11.83-5.86-18.70-38.98
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-10.043.205.004.8018.2915.29
Purchase of Investments-10.040.000.000.000.000.00
Sale Or Maturity of Investments0.003.205.004.8018.2915.29
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-10.043.205.004.8018.2915.29
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-1.3350.239.150.000.360.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-1.3350.239.150.000.360.00
Proceedsfrom Stock Options-1.9020.230.000.000.000.00
Issuance or Reduction of Debt, Net0.000.0020.540.000.000.00
Change in Long Term Debt0.000.0020.540.000.000.00
Issuance of Long Term Debt0.000.0020.790.000.000.00
Reduction of Long Term Debt0.000.00-0.250.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.9049.8029.690.000.360.00
Exchange Rate Effect-0.000.000.010.000.010.01
Net Change in Cash-35.8730.2822.87-1.05-0.05-23.69
Free Cash Flow-24.93-22.73-11.83-5.86-18.70-38.98

Revenue breakdown

License And Other2024: 32.43M 2025: 31.21M
Product2024: 112.81M 2025: 114.86M
United States2024: 145.24M 2025: 146.07M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3043.67%8.2M18.9M2.87M
2026-10-1538.55%7.3M18.9M1.77M
2026-09-3032.60%6.1M18.6M1.59M
2026-09-1542.86%7.9M18.4M1.51M
2026-08-3153.48%9.8M18.4M1.29M
2026-08-1452.54%9.6M18.4M1.21M
2026-07-3138.57%7.6M19.6M926.25K
2026-07-1532.22%6.3M19.6M452.07K
2026-06-3033.61%6.6M19.6M495.62K
2026-06-1528.51%5.6M19.6M849.26K
2026-05-2927.32%5.3M19.6M919.38K
2026-05-1526.91%5.3M19.6M938.90K
2026-04-3025.34%5.3M20.9M1.01M
2026-04-1527.49%5.7M20.8M1.02M
2026-03-3126.14%5.5M20.9M995.52K
2026-03-1321.14%3.6M17.0M541.89K
2026-02-2717.49%3.0M17.0M454.62K
2026-02-1314.52%2.5M17.0M385.92K
2026-01-307.99%1.4M16.9M263.90K
2026-01-154.33%0.7M17.2M228.45K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.050.056.15790210.000.0040.0000.000
call1.000.000.050.037.8015760.000.0420.0000.000
call1.500.000.050.028.87936.000.000.0540.0000.000
call2.000.000.050.059.58925.000.000.0610.0000.000
call2.500.000.050.0510.1142,6140.000.0660.0000.000
call5.000.000.050.1012.3861850.000.0450.0000.000
call7.500.000.050.1512.4492140.000.085-0.0010.000
call10.000.000.050.0413.0071,9880.000.089-0.0010.000
call12.500.000.050.0113.4271570.000.092-0.0010.000
call15.000.000.050.0513.7635200.000.094-0.0010.000
call17.500.000.050.0514.0435180.000.095-0.0010.000
call20.000.000.050.0014.2810.000.000.097-0.0010.000
put0.500.401.400.450.0005850.00-0.9960.0000.000
put1.000.951.750.940.00036.001.00-0.9840.0000.000
put1.500.551.551.440.0002.0012.00-0.9760.0000.000
put2.001.502.501.270.0001.000.00-0.9710.0000.000
put2.502.003.001.700.0001190.00-0.9670.0000.000
put5.004.605.604.990.00039.000.00-0.9550.0000.000
put7.507.108.107.400.0001,1250.00-0.9490.0010.000
put10.009.6010.609.940.0001.001.00-0.9460.0010.000
put12.5012.0013.0011.900.0000.000.00-0.9430.0010.000
put15.0014.5015.5014.400.0000.000.00-0.9410.0010.000
put17.5017.0018.0016.900.0000.000.00-0.9390.0020.000
put20.0019.5020.5019.400.0000.000.00-0.9370.0020.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09SCHEDULE 13G/ASEC
2026-11-058-KCurrent report2026-11-04SEC
2026-11-038-KCurrent report2026-11-02SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-28SCHEDULE 13G/ASEC
2026-10-228-KCurrent report2026-10-22SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-148-KCurrent report2026-10-13SEC
2026-10-08SCHEDULE 13G/ASEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-25SCHEDULE 13G/ASEC
2026-09-25SCHEDULE 13G/ASEC
2026-09-188-KCurrent report2026-09-17SEC
2026-09-118-KCurrent report2026-09-10SEC
2026-09-04SCHEDULE 13GSEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-318-KCurrent report2026-08-31SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-11SCHEDULE 13G/ASEC
2026-07-318-KCurrent report2026-07-30SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-28SCHEDULE 13GSEC
2026-07-178-KCurrent report2026-07-13SEC
2026-06-05SCHEDULE 13G/ASEC
2026-05-288-KCurrent report2026-05-21SEC
2026-05-27S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10002.10K2
2026-0900381
2026-080000
2026-07001.34K1
2026-060000
2026-050034.74K6
2026-04004.01K1
2026-0300197.16K3
2026-020013.51K2
2026-01001.93K2
2025-120000
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.8.46%
ADAGE CAPITAL PARTNERS GP, L.L.C.6.71%
ACORN CAPITAL ADVISORS, LLC6.70%
GOLDMAN SACHS GROUP INC6.29%
BlackRock, Inc.6.26%
Kalehua Capital Management LLC6.05%
UBS Group AG4.25%
VANGUARD CAPITAL MANAGEMENT LLC4.23%
Catalio Capital Management, LP4.15%
Avidity Partners Management LP4.08%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.99%
iShares Russell 2000 ETF2.16%
T. Rowe Price Small-Cap Value Fund, Inc.1.92%
VANGUARD EXTENDED MARKET INDEX FUND1.16%
Fidelity Small Cap Index Fund0.95%
iShares Russell 2000 Value ETF0.68%
VANGUARD RUSSELL 2000 INDEX FUND0.50%
Fidelity Extended Market Index Fund0.48%
iShares Russell 2000 Growth ETF0.36%
iShares Micro-Cap ETF0.30%

OakChart. KPTI. Cached 15 minutes.